Novo is among the backers of the life sciences tools company that will focus on acquisitions.
US-based life sciences tools company Unchained Labs has secured $25m in a series A round led by Novo Ventures, the corporate venturing arm of pharmaceutical company Novo.
The round also featured Canaan Partners and TPG Biotech.
Concurrent to revealing the series A round, Unchained also disclosed its first acquisition with Optim, an analytical instrument that enables drug developers to monitor protein stability, from life sciences company Avacta for an undisclosed amount. Optim been sold to more than 60 biopharmaceutical companies…
